Completed PHASE1 INTERVENTIONAL 2-arm NCT06182267

Maximal Use Study to Determine the Pharmacokinetics of L-arginine After Exaggerated Oral Use of COL101

A Randomized, Crossover, Controlled, Maximal Use Study to Determine the Pharmacokinetics of L-arginine After Exaggerated Oral Use of COL101 in Healthy Adult Subjects

Sponsor: Colgate Palmolive

Conditions Caries,Dental

Interventions L Arginine Sodium Fluoride

Updated 4 times since 2024 Last updated: Dec 29, 2023 Started: Nov 27, 2023 Primary completion: Dec 22, 2023 Completion: Dec 22, 2023

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT06182267, this PHASE1 trial focuses on Caries,Dental and remains completed. Sponsored by Colgate Palmolive, it has been updated 4 times since 2023, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Feb 2024 — Jul 2024 [monthly]

Completed PHASE1

Status: Active Not Recruiting → Completed
Jan 2024 — Feb 2024 [monthly]

Active Not Recruiting PHASE1

First recorded

Nov 2023

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Colgate Palmolive

Data source: Colgate Palmolive

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Fair Lawn, United States